Drug Type Small molecule drug |
Synonyms JRF 104, JRF104, XH-30002 |
Target |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 16 Aug 2021 | |
Esophageal Carcinoma | Preclinical | CN | 15 Aug 2024 | |
Acute Myeloid Leukemia | Preclinical | CN | 15 Aug 2020 | |
Acute Myeloid Leukemia | Preclinical | CN | 15 Aug 2020 | |
Acute Myeloid Leukemia | Preclinical | CN | 15 Aug 2020 |